# To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

> **NCT06378242** · PHASE1,PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- High-risk Non-muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Disitamab Vedotin for injection

## Key facts

- **NCT ID:** NCT06378242
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-14
- **Primary completion:** 2029-03-15
- **Final completion:** 2029-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378242, "To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06378242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*